



2001/02

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION

International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) BE

(51) International Patent Classification 7 :  C07D 319/06		A1	(11) International Publication Number: WO 00/68221  (43) International Publication Date: 16 November 2000 (16.11.00)
(21) International Application Number: PCT/HU00/00042		49/b, H-1036 Budapest (HU). NAGY, Kálmán [HU/HU]; Turista u. 2/a, H-1025 Budapest (HU).	
(22) International Filing Date: 5 May 2000 (05.05.00)		(74) Agent: ADVOPATENT; Office Of Patent And Trademark Attorneys, P.O. Box 11, H-1251 Budapest (HU).	
(30) Priority Data: P9901526 6 May 1999 (06.05.99) HU		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): EGIS GYÓGYSZERGYÁR RT. [HU/HU]; Keresztúri út 30-38, H-1106 Budapest (HU).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventors; and (75) Inventors/Applicants (for US only): KÓTAY NAGY, Péter [HU/HU]; Nagymező u. 73, H-2600 Vác (HU). GR-EFF, Zoltán [HU/HU]; Gyöngyvirág u. 8, H-1028 Budapest (HU). BARKÓCZY, József [HU/HU]; Szirom u. 4-6/B, H-1016 Budapest (HU). SIMIG, Gyula [HU/HU]; Hollósy S. u. 25, H-1126 Budapest (HU). BALÁZS, László [HU/HU]; Baross u. 38, H-1088 Budapest (HU). DOMÁN, Imre [HU/HU]; Mohács u. 18/B, H-1035 Budapest (HU). RÁTKAI, Zoltán [HU/HU]; Monori u. 19, H-1101 Budapest (HU). SERES, Péter [HU/HU]; Rádda Barnen u. 6, H-1153 Budapest (HU). BARTHA, Ferenc [HU/HU]; Kabay u. 3-5/S, H-4440 Tiszavasvári (HU). VERECZKEYNE DONÁTH, Györgyi [HU/HU]; Lajos u.		(54) Title: SALTS OF 2,2-DIMETHYL-1,3-DIOXANE INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF	
(57) Abstract			
<p>The invention relates to salts of (4R-cis)- -(1,1-dimethyl -ethyl) -6-(2-aminoethyl) -2,2-dimethyl -1,3-dioxane -4-acetate of formula (I) formed with organic acids. The new salts according to the invention are stable and can be easily purified by recrystallization. The new salts of the invention are valuable pharmaceutical intermediates which can be used e.g. in the preparation of the hypolipidemic agent having the generic (INN) name atorvastatin. The invention further relates to the preparation of the new salts of the compound of formula (I).</p> <p style="text-align: center;">  (I) </p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## SALTS OF 2,2-DIMETHYL-1,3-DIOXANE INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF


### FIELD OF THE INVENTION

This invention relates to new pharmaceutical intermediates and a process for the preparation thereof.

The invention relates more particularly to salts of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate formed with organic acids.


### TECHNICAL BACKGROUND

The (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate of the Formula



is a valuable pharmaceutical intermediate which can be used e.g. in the preparation of the hypolipidemical agent of the Formula


2



having the international non-proprietary name (INN) atorvastatin.


Two methods are known from prior art for the preparation of the compound of the Formula I. The process disclosed in US patent No. 5,155,251 is disclosed on reaction scheme A.

Reaction scheme A



According to this patent the aminoethyl derivative of the Formula I is prepared by fractionated distillation carried out at 125-135°C/0.05 Hgmm. The purity of the product is not higher than 96 %. The disadvantage of this process is that fractionated distillation in high vacuo is a complicated purification method which is only circumstantially feasible on industrial scale.

The process set forth in US patent No. 5,103,024 and the corresponding Hungarian patent No. 213,731 is shown on reaction scheme B.



According to this patent the compound of the Formula I is purified by column chromatography. The drawback of this process is that column chromatography requires large investments and is but difficultly feasible, particularly on industrial scale. The purity of the product obtained does not exceed 98.2 %.

The disadvantage of the above two known processes is that a product having a purity higher than 99 % can be prepared neither by means of fractional distillation nor by column chromatography.

#### ESSENCE OF THE INVENTION

It is the object of the present invention to overcome the drawbacks of the known processes and to elaborate a simple process for the preparation of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate which is preferably feasible on industrial scale too and provides a product having a purity above 99 %.

The above object is solved by the present invention.

It has been found that (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate of the Formula I forms with organic acids salts which can be excellently crystallized, are stable and of high purity. The invention compound of the Formula I being in salt form is extremely pure and can be advantageously converted into atorvastatin of the Formula II having a purity which meets the requirements of Pharmacopoeia. The advantage of the present invention is that fractionated distillation carried out in high vacuo and

column chromatography used in prior art methods are eliminated.

According to an aspect of the present invention there are provided salts of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate formed with organic acids.

According to a further aspect of the invention there is provided a process for the preparation of salts of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate formed with organic acids which comprises reacting the compound of the Formula I with an organic acid in an organic solvent.

#### DETAILS OF THE INVENTION

The present invention is based on the recognition that the compound of the Formula I forms stable salts with organic acids. This recognition is so much the more surprising as it is known from prior art that ketales are unstable in the presence of acids. The two hydroxy groups of the amine derivative of the Formula I are protected by a ketale ring. It was unforeseen that said ketale group would be resistant to organic acids under the reaction conditions used. It is particularly surprising that the salts of the present invention are not only stable at room temperature but remain stable even during recrystallization from an organic solvent carried out at higher temperature.

According to the process of the present invention the following acids may be used for salt formation: an aliphatic monocarboxylic acid, dicarboxylic acid or polycarboxylic acid,

cycloalkane carboxylic acid, aliphatic unsaturated carboxylic acid, aromatic carboxylic acid, heterocyclic carboxylic acid or sulphonic acid.

According to a preferred embodiment of our invention the following acids are used: acetic acid, butyric acid, valeric acid, isovaleric acid, pivalic acid, oxalic acid, malic acid, succinic acid, malonic acid, citric acid, cyclopropane carboxylic acid, cyclobutane carboxylic acid, cyclopentane carboxylic acid, cyclohexane carboxylic acid, fumaric acid, maleic acid, benzoic acid, m-methyl-benzoic acid, 4-methoxy-benzoic acid, 4-bromo-benzoic acid, 4-tert. butyl-benzoic acid, benzenesulfonic acid, methanesulfonic acid, p-methyl-benzenesulfonic acid, p-bromo-benzenesulfonic acid, nicotic acid, tetrahydrofuran-2-carboxylic acid or tiophen-3-carboxylic acid.

According to a particularly preferred embodiment of our invention pivalic acid is used.

The reaction may be carried out in an apolar, dipolar aprotic or protic solvent. As reaction medium an aliphatic hydrocarbon, aromatic hydrocarbon, halogenated hydrocarbon, ester, nitrile, alcohol or ether may be used. It is preferred to use one of the following solvents: hexane, heptane, petrolether, toluene, benzene, xylene, dichloro methane, chloroform, ethyl acetate, acetonitrile, methanol, ethanol, isopropanol, tetrahydrofuran, dioxane or diethyl ether.

A solvent mixture may also be used as reaction medium. It is preferred to use a mixture of heptane and toluene; hexane

and toluene; hexane, toluene and tetrahydrofuran; heptane, toluene and tetrahydrofuran; or hexane and diethyl ether.

According to a particularly preferred embodiment of our invention the compound of the Formula I and the organic acid are reacted in the form of solutions formed with the same solvent.

It is preferred to use the compound of the Formula I and the organic acid in a molar ratio of 0.5-5, preferably 0.5-2, particularly preferably 0.5-1.2.

The compound of the Formula I and the organic acid are admixed preferably at room temperature and the reaction may be performed under heating or at room temperature. One may preferably work at the boiling point of the reaction mixture.

The reaction mixture may be worked up by simple methods. One may proceed preferably by cooling the reaction mixture, isolating the precipitated salt of the compound of the Formula I by filtration or centrifugation, washing the salt with an organic solvent and drying. The salt may be purified by recrystallization.

According to a preferred embodiment of the process according to the present invention as starting material a crude compound of the Formula I is used. In this case the expensive and complicated purification of the compound of the Formula I is eliminated.

The advantages of the present invention may be summarized as follows:

According to the present invention the compound of the Formula I is purified by simple recrystallization which can be carried out significantly easier than fractionated distillation performed in high vacuo and column-chromatography used in the known methods.

The present invention provides a product of higher purity than the prior art methods. After a single recrystallization step the purity of the product is > 99 % (according to gas chromatography), after two-fold recrystallization the purity amounts to > 99.95 %. The purity of the product obtained by known methods is lower than 98 %.

The process of the present invention can be easily carried out on industrial scale too. The scaling-up causes no problems. On the other hand the fractionated distillation performed in high vacuo and column chromatography requires considerable investments and is but difficultly feasible on industrial scale.

The compound of the Formula I is stable and can be stored for a long period of time without decomposition in the form of salts formed with organic acids.

From the high purity salts of the compound of the Formula I according to the present invention atorvastatin meeting the requirements of Pharmacopoeia can be prepared.

Further details of the present invention are to be found in the following Examples without limiting the scope of protection to said Examples.

Example 1Pivalate of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate

55 g of crude oily (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 500 ml of a 4:1 mixture of heptane and toluene. 20.6 g (201 millimoles) of pivalic acid are dissolved in 190 ml of a 4:1 mixture of heptane and toluene. The two solutions are admixed and the reaction mixture is refluxed for an hour. The hot solution is filtered and the mixture is cooled with icecold water under stirring. The precipitated crystals are filtered, washed with a cold mixture of heptane and toluene and dried. Thus 64.9 g (172 millimoles) of the desired compound are obtained, yield 86 %, mp.: 131°C.

Elementary analysis: for	C%	H%	N%
calc.:	60.77	9.93	3.73
found:	60.77	9.88	3.81

TLC propanol/ammonia = 7:3,  $R_f$  = 0.63

IR (KBr): 2949, 1725, 1520, 1173.

HNMR (DMSO,  $\delta$ 400): 4.17 (m, 1H), 3.98 (m, 1H), 2.66 (m, 2H), 2.36 (dd,  $J_1=4.9$  Hz,  $J_2=15.0$  Hz, 1H), 2.22 (dd,  $J_1=8.1$  Hz,  $J_2=15.0$  Hz, 1H), 1.54 (m, 3H), 1.39 (s, 12H), 1.24 (s, 3H), 1.05 (s, 9H), 1.03 ( $\sim$ t,  $J=12.0$  Hz, 1H).

CNMR: 180.87, 169.77, 98.22, 79.85, 66.50, 66.12, 42.34, 38.26, 37.05, 36.44, 35.97, 30.11, 28.03, 27.92, 19.88.

MS: 274 (3), 202 (57), 200 (47), 173 (44), 158 (50), 57 (100), 41 (48), 30 (96).

GC content > 99%, diastereomer contamination < 0.7%.

**Example 2**

Pivalic acid salt of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate

23.3 g of one recrystallized (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate pivalic acid salt are dissolved in 220 ml of a 4:1 mixture of hexane and toluene. The solution is heated to reflux, the hot solution is filtered and the mixture is cooled with icecold water under stirring. The precipitated crystals are filtered, washed with cold diethyl ether and dried. Thus 20.7 g of the desired product are obtained, yield 89 %, mp.: 132-133°C.

GC content > 99.95 %; total impurities < 0.05 %.

**Example 3**

Pivalic acid salt of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate

21 g of crude oily (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 116 ml of a 2:2:1 mixture of hexane, toluene and tetrahydrofuran. 7.6 g (201 millimoles) of pivalic acid are dissolved in 53 ml of a 1:1 mixture of hexane and toluene. The two solutions are admixed and the reaction mixture is heated to boiling under reflux. The hot solution is filtered and the mixture is cooled with icecold water under stirring. The precipitated crystals are filtered, washed with cold diethyl ether and dried. Thus 21.1 g of the desired product are obtained. Yield 73 %, mp.: 131°C.

**Example 4****Pivalic acid salt of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate**

24 g (87.8 millimoles) of crude oily (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 200 ml of a 4:1:1 mixture of heptane, toluene and tetrahydrofuran. 9.0 g (88 millimoles) of pivalic acid are dissolved in 100 ml of a 4:1:1 mixture of heptane, toluene and tetrahydrofuran. The two solutions are admixed and the reaction mixture is heated to boiling under reflux. The hot solution is filtered and the mixture is cooled with icecold water under stirring. The precipitated crystals are filtered, washed with cold diethyl ether and dried. Thus 29.0 g of the desired compound are obtained, yield 88 %, mp.: 131°C.

**Example 5****Benzoic acid salt of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate**

0.6 g (219 millimoles) of crude (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 4 ml of ethyl acetate. 0.26 g of benzoic acid are dissolved in 8 ml of a 1:1 mixture of hexane and diethyl ether. The two solutions are admixed and stirred at room temperature for an hour. The reaction mixture is evaporated in vacuo. The residue is recrystallized from 5 ml of a 4:1 mixture of hexane and toluene. After cooling the precipitated crystals are filtered, washed with cold hexane and dried. Thus 0.71 g

of the desired compound are obtained, yield 82 %, mp.: 113-114°C.

Formula:  $C_{21}H_{33}NO_6$

Molecular weight: 395.500

Elementary analysis: for	C%	H%	N%
calc.:	63.78	8.41	3.54
found:	63.74	8.38	3.55

TLC propanol/ammonia =7:3  $R_f$ =0.63

IR (KBr): 2979, 1722, 1519, 1370.

HNMR (CDCl<sub>3</sub>, g200): 8.39 (b, 3H), 7.98 (~d,  $J=7.0$  Hz, 2H), 7.39 (m, 3H), 4.13 (m, 1H), 3.79 (m, 1H), 2.97 (m, 2H), 2.23 (m, 2H), 1.70 (m, 2H), 1.43 (s, 9H), 1.32 (s, 3H), 1.27 (s, 3H), 1.00 (m, 2H).

#### Example 6

Maleic acid salt of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate

0.6 g (219 millimoles) of crude oily (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 6 ml of diethyl ether. 0.25 g (219 millimoles) of maleic acid are dissolved in 4 ml of diethyl ether. The two solutions are admixed and stirred at room temperature. After cooling the precipitated crystals are filtered, washed with cold hexane and dried. Thus 0.80 g of the desired compound are obtained, yield 93 %, mp.: 87-89°C.

Formula:  $C_{18}H_{31}NO_8$

Molecular weight: 389.450

Elementary analysis: for	C%	H%	N%
calc.:	55.51	8.02	3.60
found:	54.70	8.12	3.52

TLC propanol/ammonia =7:3  $R_f$ =0.63.

IR (KBr):3430, 2980, 1722.

HNMR (CDCl<sub>3</sub>,  $\delta$ 400): 7.97 (b, 3H), 6.25 (s, 2H), 4.28 (m, 1H), 4.10 (m, 1H), 3.21 (m, 2H), 2.40 (m, 1H), 2.31 (m, 1H), 1.89 (m, 2H), 1.57 (m, 1H), 1.46 (s, 3H), 1.44 (s, 9H), 1.35 (s, 3H), 1.27 (m, 1H).

### Example 7

#### Fumaric acid salt of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate

0.6 g (219 millimoles) of crude oily (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 4 ml of anhydrous ethanol. 0.25 g (219 millimoles) of fumaric acid are dissolved in 10 ml of anhydrous ethanol. The two solutions are admixed and stirred at room temperature. The reaction mixture is evaporated and the residue is suspended in hexane. After cooling the precipitated crystals are filtered and recrystallized from 2-propanol. Thus 0.75 g of the desired compound are obtained, yield 85 %, mp.: 145-148°C.

Formula: C<sub>18</sub>H<sub>31</sub>NO<sub>8</sub>

Molecular weight: 389.450

Elementary analysis: for	C%	H%	N%
calc.:	55.51	8.02	3.60
found:	55.31	8.04	3.55

TLC propanol/ammonia =7:3  $R_f$ =0.63

IR (KBr): 3430, 2988, 1736, 1157.

HNMR (DMSO,  $\delta$ 200): 8.52 (b, 3H), 6.44 (s, 2H), 4.17 (m, 1H), 3.98 (m, 1H), 2.80 (m, 2H), 2.36 (m, 1H), 2.19 (m, 1H), 1.68 (m, 2H), 1.58 (m, 1H), 1.38 (m, 12H), 1.24 (m, 3H), 1.09 (m, 1H).

**Example 8**

Meta-methyl-benzoic acid salt of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate

0.6 g (219 millimoles) of crude oily (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 6 ml of diethyl ether. 0.3 g (219 millimoles) of meta-methyl-benzoic acid are dissolved in 3 ml of diethyl ether. The two solutions are admixed and stirred at room temperature. The reaction mixture is evaporated and the residue is crystallized from a 5:1 mixture of hexane and toluene. Thus 0.84 g of the desired compound are obtained, yield 92 %, mp.: 95-96°C.

Formula:  $C_{22}H_{35}NO_6$

Molecular weight: 409.527

Elementary analysis: for	C%	H%	N%
calc.:	64.52	8.61	3.42
found:	64.23	8.64	3.45

TLC propanol/ammonia =7:3  $R_f$ =0.63

IR (KBr): 2977, 2200, 1722, 1367.

HNMR (CDCl<sub>3</sub>,  $\delta$ 400): 8.86 (b, 3H), 7.79 (m, 1H), 7.77 (m, 1H), 7.24 (m, 2H), 4.13 (m, 1H), 3.79 (m, 1H), 3.02 (m, 1H), 2.93

(m, 1H), 2.37 (s, 3H), 2.31 (m, 1H), 2.18 (m, 1H), 1.71 (m, 2H), 1.50 (m, 1H), 1.43 (s, 9H), 1.33 (s, 3H), 1.26 (s, 3H), 1.00 (m, 1H).

#### Example 9

##### Benzenesulfonic acid salt of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate

0.6 g (219 millimoles) of crude oily (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 5 ml of a 4:1 mixture of hexane and toluene. 0.34 g (219 millimoles) of benzenesulfonic acid are dissolved in 5 ml of toluene. The two solutions are admixed. The reaction mixture is stirred at room temperature and evaporated in vacuo. The residue is recrystallized from a 5:1 mixture of hexane and toluene. Thus 0.76 g of the desired compound are obtained, yield 80 %, mp.: 96-98°C.

Formula:  $C_{20}H_{33}NO_7S$

Molecular weight: 431.553

Elementary analysis:

for	C%	H%	S%	N%
calc.:	55.66	7.71	7.43	3.25
found:	54.79	7.73	7.32	3.28

TLC propanol/ammonia =7:3  $R_f$  =0.63

IR (KBr): 3430, 2976, 1737, 1719, 1165.

HNMR (CDCl<sub>3</sub>, 400): 7.90 (m, 1H), 7.63 (m, 2H), 7.40 (m, 2H), 4.13 (m, 1H), 3.82 (m, 1H), 2.98 (m, 2H), 2.33 (m, 1H), 3.21 (m, 1H), 1.68 (m, 2H), 1.50 (m, 1H), 1.44 (s, 9H), 1.33 (s, 3H), 1.27 (s, 3H), 1.03 (m, 1H).

**Example 10****Acetic acid salt of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate**

0.6 g (219 millimoles) of crude oily (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 6 ml of diethyl ether. 0.131 g (219 millimoles) of acetic acid are dissolved in 5 ml of diethyl ether. The two solutions are admixed. The reaction mixture is stirred at room temperature. The crystals are filtered, washed with hexane and dried at room temperature in vacuo. Thus 0.56 g of the desired compound are obtained, yield 76 %, mp.: 76-77°C.

Formula:  $C_{16}H_{31}NO_6$

Molecular weight: 333.429

Elementary analysis: for	C%	H%	N%
calc.:	57.64	9.37	4.20
found:	57.80	9.40	4.09

TLC propanol/ammonia =7:3  $R_f$ =0.63

IR (KBr): 3430, 2986, 1731, 1157.

HNMR (CDCl<sub>3</sub>, i400): 8.18 (b, 3H), 4.26 (m, 1H), 3.97 (m, 1H), 2.93 (m, 2H), 2.43 (m, 1H), 2.29 (m, 1H), 1.96 (s, 3H), 1.80 (m, 2H), 1.56 (m, 1H), 1.44 (s, 9H), 1.44 (s, 3H), 1.34 (s, 3H), 1.22 (m, 1H).

**Example 11****Bis-(4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate oxalic acid salt**

0.6 g (219 millimoles) of crude oily (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate are dissolved in 6 ml of diethyl ether. 0.19 g (219 millimoles) of oxalic acid are dissolved in 3 ml of diethyl ether. The two solutions are admixed. The reaction mixture is stirred at room temperature. The precipitated crystals are filtered, washed with cold hexane and dried at room temperature in vacuo. Thus 0.56 g of the desired compound are obtained, yield 80 %, mp.: 76-77°C.

Formula:  $C_{30}H_{56}N_2O_{12}$

Molecular weight: 333.429

Elementary analysis: for	C%	H%	N%
calc.:	56.59	8.86	4.40
found:	56.21	8.38	4.36


TLC propanol/ammonia =7:3  $R_F$  =0.63

IR (KBr): 3430, 2982, 1739, 1575, 1161.

HNMR (CDCl<sub>3</sub>,  $\delta$ 400): 8.60 (b, 3H), 4.24 (m, 1H), 3.99 (m, 1H), 3.00 (m, 2H), 2.32 (m, 2H), 1.90 (m, 2H), 1.54 (m, 1H), 1.44 (s, 9H), 1.41 (s, 3H), 1.32 (s, 3H), 1.21 (m, 1H).

**What we claim is,**

1. Salts of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-amino-ethyl)-2,2-dimethyl-1,3-dioxane-4-acetate of the Formula



formed with organic acids.

2. Salts of the compound of the Formula I according to  
Claim 1 formed with an aliphatic monocarboxylic acid, dicarboxylic acid or polycarboxylic acid, cycloalkane carboxylic acid, aliphatic unsaturated carboxylic acid, aromatic carboxylic acid, heterocyclic carboxylic acid or sulphonic acid.

3. Salts of the compound of the Formula I according to  
Claim 2 formed with acetic acid, butyric acid, valeric acid, isovaleric acid, pivalic acid, oxalic acid, malic acid, succinic acid, malonic acid, citric acid, cyclopropane carboxylic acid, cyclobutane carboxylic acid, cyclopentane carboxylic acid, cyclohexane carboxylic acid, fumaric acid, maleic acid, benzoic acid, m-methyl-benzoic acid, 4-methoxy-benzoic acid, 4-bromo-benzoic acid, 4-tert. butyl-benzoic acid, benzenesulfonic acid, methanesulfonic acid, p-methyl-benzenesulfonic acid, p-bromo-benzenesulfonic acid, nicotic

acid, tetrahydrofuran-2-carboxylic acid or tiophen-3-carboxylic acid.

4. Salt of the compound of the Formula I according to Claim 1 formed with pivalic acid.

5. Process for the preparation of salts of (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate of the Formula I which comprises reacting (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate of the Formula I with an organic acid in an organic solvent.

6. Process according to Claim 5 which comprises using as organic acid an aliphatic monocarboxylic acid, dicarboxylic acid or polycarboxylic acid, cycloalkane carboxylic acid, aliphatic unsaturated carboxylic acid, aromatic carboxylic acid, heterocyclic carboxylic acid or sulphonic acid.

7. Process according to Claim 6 which comprises using acetic acid, butyric acid, valeric acid, isovaleric acid, pivalic acid, oxalic acid, malic acid, succinic acid, malonic acid, citric acid, cyclopropane carboxylic acid, cyclobutane carboxylic acid, cyclopentane carboxylic acid, cyclohexane carboxylic acid, fumaric acid, maleic acid, benzoic acid, m-methyl-benzoic acid, 4-methoxy-benzoic acid, 4-bromo-benzoic acid, 4-tert. butyl-benzoic acid, benzenesulfonic acid, methanesulfonic acid, p-methyl-benzenesulfonic acid, p-bromo-benzenesulfonic acid, nicotic acid, tetrahydrofuran-2-carboxylic acid or tiophen-3-carboxylic acid.

8. Process according to Claim 7 which comprises using pivalic acid.

9. Process according to any of Claims 6-8 which comprises using as reaction medium an apolar, dipolar, aprotic or protic solvent.

10. Process according to Claim 9 which comprises using as organic solvent an aliphatic hydrocarbon, aromatic hydrocarbon, halogenated hydrocarbon, ester, nitrile, alcohol or ether.

11. Process according to Claim 10 which comprises using as organic solvent hexane, heptane, petrolether, toluene, benzene, xylene, dichloro methane, chloroform, ethyl acetate, acetonitrile, methanol, ethanol, isopropanol, tetrahydrofurane, dioxane or diethyl ether.

12. Process according to any of Claims 9-11 which comprises using as reaction medium a solvent mixture.

13. Process according to Claim 12 which comprises using as reaction medium a mixture of heptane and toluene; hexane and toluene; hexane, toluene and tetrahydrofurane; heptane, toluene and tetrahydrofurane; or hexane and diethyl ether.

14. Process according to any of Claims 5-13 which comprises dissolving the compound of the Formula I and the organic acid in the same solvent and admixing the two solutions.

15. Process according to any of Claims 5-14 which comprises using the compound of the Formula I and the

organic acid in a molar ratio of 0.5-5, preferably 0.5-2, particularly preferably 0.5-1.2.

16. Process according to any of Claims 5-15 which comprises carrying out the reaction at room temperature or under warming, preferably at 20-90°C.

17. Process according to any of Claims 5-16 which comprises using as starting material crude (4R-cis)-(1,1-dimethyl-ethyl)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/HU 00042

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07D319/06

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 155 251 A (BUTLER DONALD E ET AL) 13 October 1992 (1992-10-13) cited in the application example 3 ---	1-17
Y	WO 92 06968 A (WARNER LAMBERT CO) 30 April 1992 (1992-04-30) cited in the application example 2 ---	1-17
Y	EP 0 330 172 A (WARNER LAMBERT CO) 30 August 1989 (1989-08-30) *formulae IVb, XXI, XXIIIa* claim 35; examples 1-3 ---	1-17 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

29 August 2000

Date of mailing of the international search report

12/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Härtinger, S

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/HU 00042

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BAUMANN K L ET AL: "THE CONVERGENT SYNTHESIS OF CI-981, AN OPTICALLY ACTIVE, HIGHLY POTENT, TISSUE SELECTIVE INHIBITOR OF HMG-COA REDUCTASE" TETRAHEDRON LETTERS, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 33, no. 17, 21 April 1992 (1992-04-21), pages 2283-2284, XP000608147 ISSN: 0040-4039 example 6 ---	1-17
Y	US 5 599 954 A (MITSUHASHI SIGERU ET AL) 4 February 1997 (1997-02-04) reference example 3 ---	1-17
Y	WO 98 04543 A (WARNER LAMBERT CO ;BUTLER DONALD EUGENE (US); JACKS THOMAS ELLIOTT) 5 February 1998 (1998-02-05) example 6 ---	1-17
P, Y	WO 99 57109 A (INOUE KENJI ;MITSUDA MASARU (JP); MIYAZAKI MAKOTO (JP); KANEGAFUCH) 11 November 1999 (1999-11-11) claims 1,4 ---	1-17
A	US 5 278 313 A (THOTTATHIL JOHN K ET AL) 11 January 1994 (1994-01-11) column 7, line 14 - line 54 ---	1-17
A	REESE C B: "PROTECTIVE GROUPS IN ORGANIC CHEMISTRY: PROTECTION OF GLYCOL SYSTEMS" , PROTECTIVE GROUPS IN ORGANIC CHEMISTRY, PAGES 120-143 XP002042278 page 122, paragraph 1 ---	1-17

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/HU 00042

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5155251	A	13-10-1992	AT 175190 T AU 667320 B AU 2764192 A CA 2116973 A DE 69228073 D DE 69228073 T EP 0643689 A ES 2129457 T FI 941632 A JP 7500105 T MX 9205824 A NO 941280 A PT 100943 A, B SG 46599 A WO 9307115 A ZA 9207793 A		15-01-1999 21-03-1996 03-05-1993 15-04-1993 11-02-1999 10-06-1999 22-03-1995 16-06-1999 08-04-1994 05-01-1995 01-04-1993 08-04-1994 29-10-1993 20-02-1998 15-04-1993 11-04-1994
WO 9206968	A	30-04-1992	US 5103024 A AT 118772 T AU 646311 B AU 8848091 A CA 2092997 A CZ 282922 B CZ 9701245 A CZ 9701246 A CZ 9701247 A CZ 9502094 A CZ 9300614 A DE 69107622 D DE 69107622 T DK 553213 T EP 0553213 A ES 2070519 T FI 931680 A HK 1005026 A HU 64049 A HU 213731 B IE 62940 B JP 6502162 T KR 166385 B NO 301588 B PT 99244 A, B RU 2067580 C SK 33993 A US 5248793 A		07-04-1992 15-03-1995 17-02-1994 20-05-1992 18-04-1992 12-11-1997 17-12-1997 17-12-1997 17-12-1997 17-12-1997 16-02-1994 30-03-1995 06-07-1995 17-07-1995 04-08-1993 01-06-1995 14-04-1993 18-12-1998 29-11-1993 29-09-1997 08-03-1995 10-03-1994 15-01-1999 17-11-1997 30-09-1992 10-10-1996 06-10-1993 28-09-1993
EP 0330172	A	30-08-1989	US 5003080 A AT 109777 T AU 634689 B AU 1601792 A AU 635171 B AU 1601892 A AU 3349689 A CA 1330441 A DE 68917336 D DE 68917336 T DK 197090 A EP 0448552 A		26-03-1991 15-08-1994 25-02-1993 09-07-1992 11-03-1993 09-07-1992 06-09-1989 28-06-1994 15-09-1994 01-12-1994 04-10-1990 02-10-1991

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/HK/00042

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
EP 0330172	A	ES	2058356 T	01-11-1994	
		FI	94958 B	15-08-1995	
		FI	941550 A, B,	05-04-1994	
		HK	1000732 A	24-04-1998	
		IE	63994 B	28-06-1995	
		JP	3009139 B	14-02-2000	
		JP	10195071 A	28-07-1998	
		JP	2843627 B	06-01-1999	
		JP	3502798 T	27-06-1991	
		KR	9711578 B	12-07-1997	
		KR	9711579 B	12-07-1997	
		KR	123813 B	27-11-1997	
		KR	9711462 B	11-07-1997	
		KR	137884 B	01-05-1998	
		NO	177566 B	03-07-1995	
		NO	941725 A, B,	27-09-1990	
		NO	943057 A, B,	27-09-1990	
		NO	951075 A, B,	27-09-1990	
		NO	963245 A	27-09-1990	
		NZ	228050 A	29-01-1992	
		NZ	238843 A	29-01-1992	
		NZ	238844 A	29-01-1992	
		NZ	238845 A	29-01-1992	
		PT	89774 A, B	04-10-1989	
		US	5245047 A	14-09-1993	
		US	5280126 A	18-01-1994	
		WO	8907598 A	24-08-1989	
		US	5124482 A	23-06-1992	
		US	5149837 A	22-09-1992	
		US	5216174 A	01-06-1993	
		ZA	8900989 A	31-10-1990	
		US	5097045 A	17-03-1992	
US 5599954	A	04-02-1997	JP	8198832 A	06-08-1996
WO 9804543	A	05-02-1998	AU	3515497 A	20-02-1998
			EP	0915866 A	19-05-1999
			HU	9904348 A	28-04-2000
			US	5998633 A	07-12-1999
WO 9957109	A	11-11-1999	NONE		
US 5278313	A	11-01-1994	US	5457227 A	10-10-1995
			US	5594153 A	14-01-1997